<![CDATA[GlobalCures]]>https://www.globalcures.net/blogRSS for NodeMon, 24 Aug 2026 09:04:29 GMT<![CDATA[Sintilimab - Asian-optimized PD-1 checkpoint inhibitor by Lilly and Innovent Biologics]]>https://www.globalcures.net/post/sintilimab-asian-optimized-pd-1-checkpoint-inhibitor-by-lilly-and-innovent-biologics6a89acf05802447f29d3c0fbWed, 17 Dec 2025 13:19:23 GMTEmmanuel Paredes<![CDATA[Cadonilimab — a PD-1/CTLA-4 bispecific antibody for cervical cancer and other solid tumors]]>https://www.globalcures.net/post/cadonilimab-a-pd-1-ctla-4-bispecific-antibody-for-cervical-cancer-and-other-solid-tumors6a89acf05802447f29d3c0faSat, 01 Nov 2025 03:17:32 GMTEmmanuel Paredes<![CDATA[Toripalimab — a PD-1 inhibitor for multiple solid tumors]]>https://www.globalcures.net/post/toripalimab-a-pd-1-inhibitor-for-multiple-solid-tumors6a89acf05802447f29d3c0f9Fri, 31 Oct 2025 14:18:04 GMTEmmanuel Paredes<![CDATA[Fruquintinib, a US FDA-approved inhibitor for metastatic colorectal cancer ]]>https://www.globalcures.net/post/fruquintinib6a89acee5802447f29d3c0f1Mon, 03 Feb 2025 03:55:05 GMTbuildclock<![CDATA[Tislelizumab: US FDA approved with superior efficacy in ESCC]]>https://www.globalcures.net/post/tislelizumab6a89acee5802447f29d3c0f0Mon, 03 Feb 2025 03:43:27 GMTbuildclock<![CDATA[Ivonescimab - Promising Efficacy in NSCLC]]>https://www.globalcures.net/post/ivonescimab6a89acee5802447f29d3c0edMon, 03 Feb 2025 02:59:24 GMTbuildclock